Adam Dye
Family · St George, UTNPI 1861754947
Payments from drug & device makers
Across 124 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$394
- Amgen$213
- AstraZeneca$199
- Merck$149
- Boston Scientific$123
- Boehringer Ingelheim$117
- plus $978 from 26 others
What the payments were for
- Food & beverage$2,173100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $394 |
| Amgen(2 entities) | 10 | $213 |
| AstraZeneca(2 entities) | 13 | $199 |
| Merck | 10 | $149 |
| Boston Scientific | 6 | $123 |
| Boehringer Ingelheim | 6 | $117 |
| Novo Nordisk | 6 | $94 |
| Pfizer | 4 | $74 |
| Biohaven Pharmaceuticals, Inc. | 4 | $65 |
| Lilly USA, LLC | 4 | $63 |
| Nevro Corp. | 2 | $60 |
| Johnson & Johnson | 3 | $59 |
| Organon | 3 | $56 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| IBSA Pharma Inc. | 3 | $50 |
| Lucid Diagnostics Inc. | 2 | $50 |
| Exact Sciences | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Medtronic | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Grifols USA, LLC | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $17 |
| GSK | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Bayer | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
How this compares
$2,173 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 94 | $99,405 |
| XareltoRivaroxaban | 52 | $73,742 |
| JardianceEmpagliflozin | 63 | $66,904 |
| OzempicSemaglutide | 40 | $66,174 |
| MounjaroTirzepatide | 45 | $52,992 |
| FarxigaDapagliflozin Propanediol | 33 | $43,095 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $39,708 |
| JanuviaSitagliptin Phosphate | 32 | $32,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $24,558 |
| TrulicityDulaglutide | 20 | $19,264 |
| MyrbetriqMirabegron | 21 | $17,501 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $10,304 |
| Levothyroxine Sodium | 570 | $6,741 |
| Liothyronine Sodium | 196 | $6,658 |
| Omeprazole | 245 | $4,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $99,40594 claims |
| Johnson & JohnsonXarelto | $59 | $73,74252 claims |
| Lilly USA, LLCMounjaro, Trulicity | $63 | $72,25565 claims |
| Boehringer IngelheimJardiance | $117 | $66,90463 claims |
| Novo NordiskOzempic | $94 | $66,17440 claims |
| AstraZenecaFarxiga, Symbicort | $199 | $45,30346 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $17 | $39,70834 claims |
| MerckJanuvia | $149 | $32,70432 claims |
| GSKTrelegy Ellipta | $17 | $24,55829 claims |
| AbbVieArmour Thyroid | $394 | $1,47021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.
Other family in St George
- Allie BlazzardSt George$44K
- Kelsie MontgomerySt George$15K
- Ashlee WalkerSt George$8K
- Michelle BallardSt George$8K
- Amanda TurnerSt George$8K
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.